LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1. - Dataset (ID:20237)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | SU11274 | 3.33 | uM | LJP5 | 2 | J08 | 72 | hr | 1476 | 3511 | 3694 | 0.9505 | 0.9175 |
| SK-BR-3 | SU11274 | 3.33 | uM | LJP5 | 3 | J08 | 72 | hr | 1476 | 3723 | 3694 | 1.0078 | 1.0131 |
| SK-BR-3 | Fedratinib | 3.33 | uM | LJP5 | 1 | L02 | 72 | hr | 1476 | 2135 | 3694 | 0.5780 | 0.2969 |
| SK-BR-3 | Fedratinib | 3.33 | uM | LJP5 | 2 | L02 | 72 | hr | 1476 | 2415 | 3694 | 0.6538 | 0.4232 |
| SK-BR-3 | Fedratinib | 3.33 | uM | LJP5 | 3 | L02 | 72 | hr | 1476 | 2276 | 3694 | 0.6161 | 0.3605 |
| SK-BR-3 | TGX221 | 3.33 | uM | LJP5 | 1 | H20 | 72 | hr | 1476 | 4020 | 3694 | 1.0882 | 1.1470 |
| SK-BR-3 | TGX221 | 3.33 | uM | LJP5 | 2 | H20 | 72 | hr | 1476 | 3550 | 3694 | 0.9610 | 0.9350 |
| SK-BR-3 | TGX221 | 3.33 | uM | LJP5 | 3 | H20 | 72 | hr | 1476 | 3362 | 3694 | 0.9101 | 0.8503 |
| SK-BR-3 | Torin1 | 3.33 | uM | LJP6 | 1 | O14 | 72 | hr | 1476 | 1295 | 3694 | 0.3506 | -0.0820 |
| SK-BR-3 | Torin1 | 3.33 | uM | LJP6 | 2 | O14 | 72 | hr | 1476 | 1071 | 3694 | 0.2899 | -0.1830 |
| SK-BR-3 | Torin1 | 3.33 | uM | LJP6 | 3 | O14 | 72 | hr | 1476 | 1210 | 3694 | 0.3276 | -0.1203 |
| SK-BR-3 | Torin2 | 3.33 | uM | LJP5 | 1 | I20 | 72 | hr | 1476 | 1073 | 3694 | 0.2905 | -0.1821 |
| SK-BR-3 | Torin2 | 3.33 | uM | LJP5 | 2 | I20 | 72 | hr | 1476 | 1211 | 3694 | 0.3278 | -0.1198 |
| SK-BR-3 | Torin2 | 3.33 | uM | LJP5 | 3 | I20 | 72 | hr | 1476 | 1147 | 3694 | 0.3105 | -0.1487 |
| SK-BR-3 | Tozasertib | 3.33 | uM | LJP5 | 1 | B14 | 72 | hr | 1476 | 1277 | 3694 | 0.3457 | -0.0901 |
| SK-BR-3 | Tozasertib | 3.33 | uM | LJP5 | 2 | B14 | 72 | hr | 1476 | 1309 | 3694 | 0.3544 | -0.0756 |
| SK-BR-3 | Tozasertib | 3.33 | uM | LJP5 | 3 | B14 | 72 | hr | 1476 | 1292 | 3694 | 0.3498 | -0.0833 |
| SK-BR-3 | Trametinib | 3.33 | uM | LJP5 | 1 | P20 | 72 | hr | 1476 | 2656 | 3694 | 0.7190 | 0.5319 |
| SK-BR-3 | Trametinib | 3.33 | uM | LJP5 | 2 | P20 | 72 | hr | 1476 | 2604 | 3694 | 0.7049 | 0.5084 |
| SK-BR-3 | Trametinib | 3.33 | uM | LJP5 | 3 | P20 | 72 | hr | 1476 | 2725 | 3694 | 0.7377 | 0.5630 |
| SK-BR-3 | TWS119 | 3.33 | uM | LJP5 | 1 | M02 | 72 | hr | 1476 | 2450 | 3694 | 0.6632 | 0.4389 |
| SK-BR-3 | TWS119 | 3.33 | uM | LJP5 | 2 | M02 | 72 | hr | 1476 | 2369 | 3694 | 0.6413 | 0.4024 |
| SK-BR-3 | TWS119 | 3.33 | uM | LJP5 | 3 | M02 | 72 | hr | 1476 | 2528 | 3694 | 0.6843 | 0.4741 |
| SK-BR-3 | Vemurafenib | 3.33 | uM | LJP5 | 1 | C14 | 72 | hr | 1476 | 3616 | 3694 | 0.9789 | 0.9648 |
| SK-BR-3 | Vemurafenib | 3.33 | uM | LJP5 | 2 | C14 | 72 | hr | 1476 | 3570 | 3694 | 0.9664 | 0.9441 |